AB GLOBAL DEVELOPED HEALTH CARE

Preview

E
Equity
SF
Structured funds
< Low riskHigh risk >
SRI1234567
ISIN codeAUMStarting dateNAVClass-Currency
LU274448857320,763,397.16 As of 18/06/2024 2024/04/18 96.65 As of 18/06/2024 I - EUR

Strategy

The investment objective of the Fund is to outperform the Solactive Developed Markets Broad Health Care EUR Index NTR (SDMBHCEN) (the "Benchmark Index") over a long-term horizon by exploiting investment opportunities on the equity markets. The Benchmark Index is a broad liquid equity index (approximately 840 stocks) which intends to track the performance of Health Care companies from the Developed Markets within the Solactive Global Benchmark Series and the Solactive United States Benchmark Series. The Fund is actively managed, the equity exposure may significantly deviate from the components of the Benchmark Index. The fund is article 8 of SFDR. Within the Investment Universe, equities composing the Portfolio will be selected by the Investment Manager, according to their ESG scoring, based on a best-in-class approach. Equities of the Investment Universe will be ranked using proprietary ESG materiality weightings, and a combination of fundamental ESG scores and third-party ESG management assessments; the Investment Manager’s ESG research is used to determine ESG risk factor scores. The selection of equities composing the portfolio is achieved by excluding at least 20% of the stocks comprising the investment universe with the lowest rating. More than 90% of the equities composing the Portfolio do benefit from an ESG rating. The Portfolio will be rebalanced monthly respecting the methodology. However, the Management Company may decide to rebalance the Portfolio at any time at its discretion (the "Rebalancing Date"). The exposure of the Fund to equities through the Portfolio may vary between 0% and 150% on a weekly basis at least. As a result, the exposure may drift between such adjustments. The Fund distributes a fixed dividend of EUR 5 per fund unit per year, divided into 12 identical monthly payments.

Performances

There is insufficient data to provide investors with a useful indication of past performance

Characteristics

Fund features
Placement duration 5 years
Domiciliation LUXEMBOURG
Legal type SICAV
Accounting currency EUR
Management company SG 29 HAUSSMANN
Administrator SOCIETE GENERALE SECURITIES SERVICES LUX
UCITS/AIFM UCITS
Fund passporting FRANCE,LUXEMBOURG,CZECH-REPUBLIC
Benchmark From 2024/04/18 : Solactive Developed Markets Broad Health Care EUR Index NTR
Share class characteristics
ISIN code LU2744488573
Currency EUR
NAV 96.65 EUR
Maximum management fees 0.93%
Maximum performance fees
Minimum investment 1,000.00
Min subsequent subscription None
Data as of 18/06/2024

Documents

Reports

Monthly report (FREN)

Documents

Prospectus (FREN)

KID PRIIPS (FRENCZ)

Sustainability information – Article 10 (EN)

Sustainability information – Article 10 - Summary (FRENCZ)

 

This page contains information of an advertising nature. It does not constitute a contractual commitment, investment advice or any other investment service, nor tax advice, and is not sufficient for making an investment decision. All information is provided for information purposes only and is subject to change without notice. SG 29 Haussmann cannot be held responsible for any consequences, particularly financial, resulting from transactions on financial instruments concluded on the basis of this information alone.

Please refer to the fund's prospectus and key information document before making any final investment decision. We invite you to take particular note of the risks and costs associated with this fund, as well as the recommended investment period and information relating to the subscribers concerned. Please note that past performance is no guarantee of the fund's future performance. We draw your attention to the fact that capital is not guaranteed and that investors may lose all or part of the capital invested. Finally, we invite you to contact your investment advisor on a regular basis to determine whether the planned investment is compatible with your personal situation, profile and investment objectives.